Sign in or create an account to add this stock to your watchlist.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company operates DaVita Rx, a pharmacy that provides oral medications and medication management services to patients with ESRD; disease management services; vascular access services; clinical research programs; physician services; and direct primary care services. As of December 31, 2017, it provided dialysis and administrative services in the United States through a network of 2,510 outpatient dialysis centers serving approximately 197,800 patients; and operated 237 outpatient dialysis centers located in 11 countries outside of the United States. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.
Industry, Sector and Symbol
Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryHealth Care Services
SectorMedical
SymbolNYSE:DVA
CUSIP23918K10
Phone303-405-2100
Debt
Debt-to-Equity Ratio1.94
Current Ratio2.94
Quick Ratio2.90
Price-To-Earnings
Trailing P/E Ratio20.45
Forward P/E Ratio16.56
P/E Growth0.99
Sales & Book Value
Annual Sales$10.88 billion
Price / Sales1.09
Cash Flow$7.7060 per share
Price / Cash8.81
Book Value$27.40 per share
Price / Book2.48
Profitability
EPS (Most Recent Fiscal Year)$3.32
Net Income$663.61 million
Net Margins2.94%
Return on Equity13.84%
Return on Assets3.61%
Miscellaneous
Employees74,500
Outstanding Shares174,500,000
DaVita (NYSE:DVA) Frequently Asked Questions
What is DaVita's stock symbol?
DaVita trades on the New York Stock Exchange (NYSE) under the ticker symbol "DVA."
How will DaVita's stock buyback program work?
DaVita declared that its board has initiated a share repurchase program on Wednesday, October 11th 2017, which permits the company to buyback $1,500,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to repurchase shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company's leadership believes its shares are undervalued.
How were DaVita's earnings last quarter?
DaVita (NYSE:DVA) announced its quarterly earnings results on Thursday, May, 3rd. The company reported $1.05 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.92 by $0.13. The business had revenue of $2.85 billion for the quarter, compared to the consensus estimate of $2.79 billion. DaVita had a net margin of 2.94% and a return on equity of 13.84%. The company's quarterly revenue was up 8.3% on a year-over-year basis. During the same period last year, the business earned $0.79 EPS. View DaVita's Earnings History.
When is DaVita's next earnings date?
What price target have analysts set for DVA?
10 brokerages have issued 12 month target prices for DaVita's stock. Their predictions range from $60.00 to $97.00. On average, they expect DaVita's share price to reach $81.1250 in the next year. View Analyst Ratings for DaVita.
Who are some of DaVita's key competitors?
Who are DaVita's key executives?
DaVita's management team includes the folowing people:
- Mr. Kent J. Thiry, Chairman & CEO (Age 62)
- Mr. James K. Hilger, Chief Accounting Officer (Age 56)
- Ms. Kathleen Alyce Waters, Chief Legal Officer (Age 50)
- Mr. Javier J. Rodriguez, Chief Exec. Officer of Kidney Care (Age 47)
- Ms. LeAnne M. Zumwalt, Group VP of Purchasing & Public Affairs (Age 59)
Has DaVita been receiving favorable news coverage?
Media coverage about DVA stock has been trending positive on Sunday, Accern Sentiment reports. The research group scores the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. DaVita earned a media sentiment score of 0.27 on Accern's scale. They also assigned headlines about the company an impact score of 47.38 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are DaVita's major shareholders?
DaVita's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.09%), Manning & Napier Group LLC (2.09%), Dimensional Fund Advisors LP (1.58%), OppenheimerFunds Inc. (1.47%), Northern Trust Corp (1.19%) and Neuberger Berman Group LLC (1.18%). Company insiders that own DaVita stock include Charles Berg, James K Hilger, Javier Rodriguez, Jeanine Marie Jiganti, Kent J Thiry, Leanne M Zumwalt, Michael David Staffieri and William L Roper. View Institutional Ownership Trends for DaVita.
Which major investors are selling DaVita stock?
DVA stock was sold by a variety of institutional investors in the last quarter, including Park West Asset Management LLC, FIL Ltd, Neuberger Berman Group LLC, Manning & Napier Group LLC, DekaBank Deutsche Girozentrale, BlackRock Inc., Prudential Financial Inc. and Sei Investments Co.. Company insiders that have sold DaVita company stock in the last year include Charles Berg, James K Hilger, Javier Rodriguez, Kent J Thiry, Leanne M Zumwalt and William L Roper. View Insider Buying and Selling for DaVita.
Which major investors are buying DaVita stock?
DVA stock was acquired by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Boston Partners, Wedge Capital Management L L P NC, Old Mutual Global Investors UK Ltd., Rock Springs Capital Management LP, Pendal Group Ltd, Mackay Shields LLC and Toronto Dominion Bank. View Insider Buying and Selling for DaVita.
How do I buy shares of DaVita?
Shares of DVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is DaVita's stock price today?
One share of DVA stock can currently be purchased for approximately $67.89.
How big of a company is DaVita?
DaVita has a market capitalization of $11.85 billion and generates $10.88 billion in revenue each year. The company earns $663.61 million in net income (profit) each year or $3.32 on an earnings per share basis. DaVita employs 74,500 workers across the globe.
How can I contact DaVita?
DaVita's mailing address is 2000 16TH STREET, DENVER CO, 80202. The company can be reached via phone at 303-405-2100 or via email at [email protected]
MarketBeat Community Rating for DaVita (DVA)
MarketBeat's community ratings are surveys of what our community members think about DaVita and other stocks. Vote "Outperform" if you believe DVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
DaVita (NYSE:DVA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
10 Wall Street analysts have issued ratings and price targets for DaVita in the last 12 months. Their average twelve-month price target is $81.1250, suggesting that the stock has a possible upside of 19.49%. The high price target for DVA is $97.00 and the low price target for DVA is $60.00. There are currently 4 hold ratings, 4 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Hold |
| Consensus Rating Score: | 2.80 | 2.64 | 2.64 | 1.89 |
| Ratings Breakdown: | 0 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
2 Strong Buy Rating(s) | 1 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
2 Strong Buy Rating(s) | 1 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
2 Strong Buy Rating(s) | 2 Sell Rating(s)
6 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $81.1250 | $79.00 | $79.00 | $63.00 |
| Price Target Upside: | 19.49% upside | 5.86% upside | 5.86% upside | 14.57% upside |
DaVita (NYSE:DVA) Consensus Price Target History
DaVita (NYSE:DVA) Analyst Ratings History
Show:
(Data available from 5/27/2016 forward)
DaVita (NYSE:DVA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
DaVita (NYSE DVA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.95%
Institutional Ownership Percentage: 87.62%
DaVita (NYSE DVA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/22/2018 | William L Roper | Director | Sell | 1,505 | $68.22 | $102,671.10 | 46,733 |  |
| 5/14/2018 | Charles Berg | Director | Sell | 338 | $66.25 | $22,392.50 | 29,776 | |
| 1/16/2018 | James K Hilger | Insider | Sell | 3,572 | $78.95 | $282,009.40 | 33,649 | |
| 12/11/2017 | Charles Berg | Insider | Sell | 7,048 | $69.24 | $488,003.52 | 5,359 | |
| 12/8/2017 | Kent J Thiry | Chairman | Sell | 81,800 | $68.04 | $5,565,672.00 | | |
| 12/8/2017 | Leanne M Zumwalt | VP | Sell | 949 | $68.19 | $64,712.31 | 12,423 | |
| 12/7/2017 | James K Hilger | Insider | Sell | 5,608 | $69.46 | $389,531.68 | 47,649 | |
| 12/7/2017 | Javier Rodriguez | CEO | Sell | 22,532 | $67.48 | $1,520,459.36 | 210,317 | |
| 5/15/2017 | Javier Rodriguez | CEO | Sell | 1,294 | $66.21 | $85,675.74 | 99,111 | |
| 5/9/2017 | Charles Berg | Director | Sell | 8,414 | $65.80 | $553,641.20 | 34,719 | |
| 5/4/2017 | William L Roper | Director | Sell | 12,994 | $65.89 | $856,174.66 | 45,277 | |
| 8/9/2016 | Michael David Staffieri | COO | Sell | 20,262 | $73.09 | $1,480,949.58 | 52,279 | |
| 7/11/2016 | Jeanine Marie Jiganti | Insider | Sell | 1,291 | $78.51 | $101,356.41 | 5,716 | |
| 7/1/2016 | Jeanine Marie Jiganti | Insider | Sell | 4,620 | $77.45 | $357,819.00 | 7,590 | |
| 5/25/2016 | Pamela M Arway | Director | Sell | 10,824 | $77.16 | $835,179.84 | 36,394 | |
| 5/23/2016 | James K Hilger | CFO | Sell | 3,416 | $76.79 | $262,314.64 | 29,147 | |
| 5/20/2016 | Kent J Thiry | CEO | Sell | 32,880 | $76.99 | $2,531,431.20 | 39,184 | |
| 5/17/2016 | Dennis Kogod | CEO | Sell | 17,700 | $77.35 | $1,369,095.00 | 18,766 | |
| 5/17/2016 | Leanne M Zumwalt | VP | Sell | 538 | $77.08 | $41,469.04 | 8,585 | |
| 5/16/2016 | James K Hilger | CFO | Sell | 3,983 | $75.59 | $301,074.97 | 21,130 | |
| 5/16/2016 | Javier Rodriguez | CEO | Sell | 36,466 | $75.44 | $2,750,995.04 | 64,264 | |
| 5/16/2016 | Michael David Staffieri | COO | Sell | 4,934 | $75.69 | $373,454.46 | 12,279 | |
| 5/12/2016 | Roger Valine | Director | Sell | 8,220 | $76.34 | $627,514.80 | 18,324 | |
| 5/10/2016 | Dennis Kogod | CEO | Sell | 40,048 | $76.25 | $3,053,660.00 | 92,716 | |
| 5/6/2016 | John M Nehra | Director | Sell | 16,314 | $75.56 | $1,232,685.84 | 36,665 | |
| 4/11/2016 | Javier Rodriguez | CEO | Sell | 89,912 | $73.51 | $6,609,431.12 | 317,397 | |
| 3/21/2016 | Dennis Kogod | CEO | Sell | 13,455 | $72.12 | $970,374.60 | 92,716 | |
| 2/29/2016 | Pamela M Arway | Director | Sell | 9,026 | $66.00 | $595,716.00 | 36,070 | |
| 2/23/2016 | Leanne M. Zumwalt | VP | Sell | 14,587 | $64.25 | $937,214.75 | | |
| 2/16/2016 | Dennis Kogod | CEO | Sell | 33,290 | $61.99 | $2,063,647.10 | 120,816 | |
| 1/13/2016 | Christopher James Schnarr | Insider | Buy | 5,000 | $0.68 | $3,400.00 | | |
| 1/11/2016 | Christopher James Schnarr | Insider | Buy | 10,000 | $0.60 | $6,000.00 | | |
| 12/17/2015 | Laura Mildenberger | insider | Sell | 1,440 | $68.14 | $98,121.60 | 8,447 | |
| 9/22/2015 | Kim M. Rivera | insider | Sell | 40,037 | $75.48 | $3,021,992.76 | 7,438 | |
| 8/17/2015 | Carol Anthony Davidson | Director | Sell | 4,038 | $79.93 | $322,757.34 | | |
| 6/4/2015 | Robert J Margolis | Chairman | Sell | 31,400 | $83.39 | $2,618,446.00 | | |
| 5/28/2015 | Michael David Staffieri | COO | Sell | 9,050 | $84.07 | $760,833.50 | | |
| 5/19/2015 | Robert J Margolis | Chairman | Sell | 15,700 | $83.22 | $1,306,554.00 | | |
| 5/18/2015 | James K Hilger | CFO | Sell | 3,983 | $82.10 | $327,004.30 | | |
| 5/18/2015 | Michael David Staffieri | COO | Sell | 2,047 | $82.03 | $167,915.41 | | |
| 5/18/2015 | Robert J Margolis | Chairman | Sell | 15,700 | $82.24 | $1,291,168.00 | | |
| 5/11/2015 | James K Hilger | CFO | Sell | 8,267 | $82.00 | $677,894.00 | | |
| 5/11/2015 | Jeanine Marie Jiganti | Insider | Sell | 2,481 | $81.95 | $203,317.95 | | |
| 5/11/2015 | John M Nehra | Director | Sell | 12,278 | $81.85 | $1,004,954.30 | | |
| 4/21/2015 | Robert J Margolis | Chairman | Sell | 31,400 | $82.40 | $2,587,360.00 | | |
| 4/7/2015 | Robert J Margolis | Chairman | Sell | 15,700 | $82.15 | $1,289,755.00 | | |
| 4/6/2015 | Robert J Margolis | Chairman | Sell | 15,700 | $81.49 | $1,279,393.00 | | |
| 3/27/2015 | Robert J Margolis | Chairman | Sell | 31,400 | $81.18 | $2,549,052.00 | | |
| 3/12/2015 | Robert J Margolis | Chairman | Sell | 107,374 | $79.24 | $8,508,315.76 | | |
| 2/27/2015 | Robert J Margolis | Chairman | Sell | 21,000 | $74.29 | $1,560,090.00 | | |
| 2/19/2015 | Robert J Margolis | Chairman | Sell | 21,000 | $73.12 | $1,535,520.00 | | |
| 1/30/2015 | Robert J Margolis | Chairman | Sell | 31,400 | $75.48 | $2,370,072.00 | | |
| 1/23/2015 | Michael David Staffieri | COO | Sell | 21,869 | $76.05 | $1,663,137.45 | | |
| 1/16/2015 | Robert J Margolis | Chairman | Sell | 31,400 | $74.92 | $2,352,488.00 | | |
| 1/8/2015 | Kim M Rivera | Insider | Sell | 1,111 | $75.10 | $83,436.10 | | |
| 12/30/2014 | Robert J Margolis | Chairman | Sell | 31,400 | $76.09 | $2,389,226.00 | | |
| 12/29/2014 | Robert J Margolis | Chairman | Sell | 15,700 | $76.09 | $1,194,613.00 | | |
| 12/19/2014 | Laura Mildenberger | Insider | Sell | 1,446 | $75.50 | $109,173.00 | | |
| 12/18/2014 | Robert J Margolis | Chairman | Sell | 31,400 | $74.67 | $2,344,638.00 | | |
| 12/3/2014 | Robert J Margolis | Chairman | Sell | 31,400 | $75.80 | $2,380,120.00 | | |
| 12/1/2014 | Kim M Rivera | Insider | Sell | 6,503 | $76.08 | $494,748.24 | | |
| 11/21/2014 | Robert J Margolis | Chairman | Sell | 31,400 | $75.08 | $2,357,512.00 | | |
| 11/11/2014 | Kent J Thiry | CEO | Sell | 344,938 | $74.52 | $25,704,779.76 | | |
| 11/11/2014 | Robert J Margolis | Chairman | Sell | 250,000 | $75.09 | $18,772,500.00 | | |
| 11/10/2014 | Berkshire Hathaway Inc | Major Shareholder | Buy | 944,418 | $74.11 | $69,990,817.98 | | |
| 11/7/2014 | R. Ted Weschler | Major Shareholder | Buy | 820,018 | $74.10 | $60,763,333.80 | | |
| 11/3/2014 | Roger Valine | Director | Sell | 7,185 | $77.85 | $559,352.25 | | |
| 9/16/2014 | John M Nehra | Director | Sell | 20,000 | $73.91 | $1,478,200.00 | | |
| 9/8/2014 | Kim M Rivera | Insider | Sell | 1,111 | $74.25 | $82,491.75 | | |
| 8/27/2014 | Leanne M Zumwalt | VP | Sell | 3,214 | $74.57 | $239,667.98 | | |
| 8/11/2014 | Jeanine Marie Jiganti | Insider | Sell | 2,500 | $72.14 | $180,350.00 | | |
| 6/11/2014 | Kim M Rivera | Insider | Sell | 5,929 | $71.05 | $421,255.45 | | |
| 5/29/2014 | Laura Mildenberger | Insider | Sell | 5,080 | $69.99 | $355,549.20 | | |
| 5/16/2014 | Dennis Kogod | COO | Sell | 18,750 | $67.30 | $1,261,875.00 | 40,874 | |
| 5/16/2014 | Kent Thiry | CEO | Sell | 17,600 | $67.41 | $1,186,416.00 | 247,950 | |
| 5/15/2014 | James Hilger | CAO | Sell | 1,666 | $67.23 | $112,005.18 | 13,277 | |
| 5/15/2014 | Javier Rodriguez | CEO | Sell | 7,000 | $67.50 | $472,500.00 | 64,264 | |
| 5/12/2014 | Dennis Kogod | COO | Sell | 32,188 | $68.06 | $2,190,715.28 | 59,624 | |
| 5/8/2014 | Dennis Kogod | COO | Sell | 32,213 | $67.36 | $2,169,867.68 | 59,624 | |
| 5/7/2014 | Michael David Staffieri | COO | Sell | 2,633 | $67.30 | $177,200.90 | | |
| 4/2/2014 | Michael David Staffieri | COO | Sell | 2,867 | $69.15 | $198,253.05 | 2,633 | |
| 3/20/2014 | Laura Mildenberger | Insider | Sell | 3,274 | $70.04 | $229,310.96 | 6,036 | |
| 2/26/2014 | R. Ted Weschler | major shareholder | Buy | 1,159,858 | $66.97 | $77,675,690.26 | 2,191,806 | |
| 2/21/2014 | John Nehra | Director | Sell | 40,000 | $65.81 | $2,632,400.00 | 81,766 | |
| 2/18/2014 | William Roper | Director | Sell | 42,519 | $66.37 | $2,821,986.03 | 4,994 | |
| 12/20/2013 | Laura Mildenberger | Insider | Sell | 10,417 | $62.53 | $651,375.01 | 6,036 | |
| 12/17/2013 | Allen Nissenson | Insider | Sell | 2,929 | $59.83 | $175,242.07 | 2,508 | |
| 12/9/2013 | Berkshire Hathaway Inc | major shareholder | Buy | 1,314,170 | $57.84 | $76,011,592.80 | | |
| 11/8/2013 | R. Ted Weschler | major shareholder | Buy | 3,700,294 | $55.14 | $204,034,211.16 | 1,095,903 | |
| 7/5/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 110,309 | $114.01 | $12,576,329.09 | | |
| 7/3/2013 | R. Ted Weschler | Major Shareholder | Buy | 639,200 | $114.78 | $73,367,376.00 | | |
| 5/15/2013 | David T Shapiro | Insider | Sell | 8,779 | $129.80 | $1,139,514.20 | | |
| 5/15/2013 | Dennis Kogod | COO | Sell | 21,130 | $129.47 | $2,735,701.10 | | |
| 5/15/2013 | James K Hilger | CFO | Sell | 1,049 | $130.18 | $136,558.82 | | |
| 5/15/2013 | Leanne M Zumwalt | VP | Sell | 13,209 | $129.59 | $1,711,754.31 | | |
| 5/13/2013 | Kent J Thiry | CEO | Sell | 243,307 | $129.95 | $31,617,744.65 | | |
| 5/13/2013 | Kim M Rivera | Insider | Sell | 1,672 | $129.70 | $216,858.40 | | |
| 3/4/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 164,947 | $119.59 | $19,726,011.73 | | |
| 3/4/2013 | Roger Valine | Director | Sell | 1,390 | $120.00 | $166,800.00 | | |
| 2/27/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 211,889 | $116.56 | $24,697,781.84 | | |
| 2/22/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 224,091 | $115.88 | $25,967,665.08 | | |
| 2/19/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 323,070 | $116.73 | $37,711,961.10 | | |
| 2/5/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 32,376 | $115.17 | $3,728,743.92 | | |
| 2/4/2013 | Roger Valine | Director | Sell | 1,389 | $116.13 | $161,304.57 | | |
| 1/16/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 42,400 | $111.33 | $4,720,392.00 | | |
| 1/15/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 179,300 | $109.67 | $19,663,831.00 | | |
| 1/10/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 187,898 | $109.54 | $20,582,346.92 | | |
| 12/24/2012 | Dennis Kogod | COO | Sell | 12,736 | $111.00 | $1,413,696.00 | | |
| 12/21/2012 | James K Hilger | CFO | Sell | 2,073 | $112.20 | $232,590.60 | | |
| 12/6/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 635,633 | $106.20 | $67,504,224.60 | | |
| 11/29/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 679,249 | $108.20 | $73,494,741.80 | | |
| 11/26/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 412,050 | $110.38 | $45,482,079.00 | | |
| 11/16/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 132,958 | $112.45 | $14,951,127.10 | | |
| 11/12/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 548,823 | $112.15 | $61,550,499.45 | | |
| 11/7/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 139,491 | $112.03 | $15,627,176.73 | | |
| 11/2/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 254,750 | $112.20 | $28,582,950.00 | | |
| 10/26/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 257,941 | $111.14 | $28,667,562.74 | | |
| 10/17/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 63,928 | $109.56 | $7,003,951.68 | | |
| 10/12/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 217,597 | $109.76 | $23,883,446.72 | | |
| 10/9/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 67,946 | $107.71 | $7,318,463.66 | | |
| 9/28/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 282,403 | $102.03 | $28,813,578.09 | | |
| 8/8/2012 | Kent J Thiry | Chairman | Sell | 320,877 | $96.88 | $31,086,563.76 | | |
| 8/7/2012 | William L Roper | Director | Sell | 23,019 | $95.95 | $2,208,673.05 | | |
(Data available from 1/1/2013 forward)
DaVita (NYSE DVA) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Insider Selling: DaVita (DVA) Director Sells 1,505 Shares of Stock
www.americanbankingnews.com - May 24 at 7:50 PM |
 | Notable Wednesday Option Activity: DVA, GT, PXD
www.nasdaq.com - May 24 at 8:15 AM |
 | Briefcase: DaVita doctor honored by Renal Physicians Association
www.bizjournals.com - May 21 at 5:12 PM |
 | Form 4 DAVITA INC. For: May 15 Filed by: HEARTY JAMES O
www.streetinsider.com - May 18 at 6:05 PM |
| Form 4 DAVITA INC. For: May 15 Filed by: ACKERMAN JOEL
www.streetinsider.com - May 18 at 6:05 PM |
| Form 4 DAVITA INC. For: May 15 Filed by: DIAZ PAUL J
www.streetinsider.com - May 18 at 8:29 AM |
| Form 4 DAVITA INC. For: May 15 Filed by: YALE PHYLLIS R
www.streetinsider.com - May 18 at 8:29 AM |
| DaVita (DVA) Expected to Post Earnings of $0.98 Per Share
www.americanbankingnews.com - May 17 at 7:28 PM |
| Form 4 DAVITA INC. For: May 14 Filed by: BERG CHARLES
www.streetinsider.com - May 17 at 8:18 AM |
| DaVita (DVA) Director Sells $22,392.50 in Stock
www.americanbankingnews.com - May 16 at 10:28 PM |
 | DaVita Teammates Volunteer with Bridge of Life and the Syrian American Medical Society to Support Health Care ...
www.prnewswire.com - May 16 at 8:15 AM |
 | Complimentary Breakfast Technical Briefing on DaVita and Three Specialized Health Services Stocks
finance.yahoo.com - May 16 at 8:15 AM |
| DaVita Teammates Volunteer with Bridge of Life and the Syrian American Medical Society to Support Health Care Needs of Syrian Refugees in Jordan
finance.yahoo.com - May 16 at 8:15 AM |
| DaVita Sees Unusually High Options Volume (DVA)
www.americanbankingnews.com - May 16 at 6:36 AM |
| Critical Analysis: Catasys (CATS) vs. DaVita (DVA)
www.americanbankingnews.com - May 15 at 11:16 PM |
| Contrasting DaVita (DVA) and Catasys (CATS)
www.americanbankingnews.com - May 15 at 3:08 AM |
| Comparing Caladrius Biosciences (CLBS) & DaVita (DVA)
www.americanbankingnews.com - May 13 at 11:16 PM |
| DaVita (DVA) versus Caladrius Biosciences (CLBS) Financial Comparison
www.americanbankingnews.com - May 12 at 1:25 PM |
 | BRIEF-Berkshire Hathaway Inc Reports 22.1 Percent Stake In Davita Inc As Of May 3, 2018
www.reuters.com - May 11 at 6:02 PM |
| Form 4 DAVITA INC. For: May 06 Filed by: Waters Kathleen Alyce
www.streetinsider.com - May 9 at 5:38 PM |
| DaVita Endorses International Initiative Aimed at Helping Give Patients a Voice in Kidney Care Trials and Research
finance.yahoo.com - May 8 at 8:13 AM |
| RN, Case Manager, Per Diem
www.bizjournals.com - May 7 at 8:16 AM |
| Health Care Heroes: DaVita Celebrates its Kidney Care Nurses During National Nurses Week
finance.yahoo.com - May 7 at 8:16 AM |
| William Blair Brokers Raise Earnings Estimates for Davita Inc (DVA)
www.americanbankingnews.com - May 7 at 2:28 AM |
| Davita Inc (DVA) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 7 at 1:40 AM |
| RN, Care Manager
www.bizjournals.com - May 6 at 7:45 PM |
| Davita (DVA) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 5 at 12:46 AM |
 | DaVita (DVA) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 4 at 8:16 AM |
| Edited Transcript of DVA earnings conference call or presentation 3-May-18 9:00pm GMT
finance.yahoo.com - May 4 at 8:16 AM |
| BRIEF-DaVita Reports Q1 Earnings Per Share $1.05 From Continuing Operations
www.reuters.com - May 3 at 5:29 PM |
| DaVita HealthCare Partners Inc. Q1 adjusted earnings of $1.05 per share
www.nasdaq.com - May 3 at 5:29 PM |
| DaVita HealthCare: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 5:29 PM |
| DaVita Inc. 1st Quarter 2018 Results
finance.yahoo.com - May 3 at 5:29 PM |
| DaVita's Sustainability Efforts Rewarded by Department of Energy
finance.yahoo.com - May 2 at 5:39 PM |
| Head to Head Comparison: Tivity Health (TVTY) and Davita (DVA)
www.americanbankingnews.com - May 2 at 3:24 PM |
| Zacks: Brokerages Anticipate Davita Inc (DVA) Will Announce Quarterly Sales of $2.96 Billion
www.americanbankingnews.com - May 2 at 4:32 AM |
| Davita Inc (DVA) Expected to Announce Earnings of $0.92 Per Share
www.americanbankingnews.com - April 30 at 7:33 AM |
| Davita (DVA) & Caladrius Biosciences (CLBS) Head to Head Survey
www.americanbankingnews.com - April 29 at 9:20 AM |
| Critical Analysis: Davita (DVA) vs. Tivity Health (TVTY)
www.americanbankingnews.com - April 29 at 1:18 AM |
| BRIEF-DaVita Says CEO Kent Thiry's Total 2017 Compensation Was $15.3 Mln
www.reuters.com - April 28 at 8:24 AM |
| Methodist launching data-sharing program to keep transplant candidates ready to receive
finance.yahoo.com - April 27 at 5:17 PM |
 | Global Dialysis Market 2018 Forecast to 2022 - Key Players are Fresenius Medical Care, DaVita, Baxter and B. Braun ...
www.businesswire.com - April 27 at 8:26 AM |
| DaVita Continues to Improve Patient Care, Leads in Five-Star Quality Ratings
finance.yahoo.com - April 27 at 8:26 AM |
| Davita Target of Unusually Large Options Trading (DVA)
www.americanbankingnews.com - April 26 at 7:14 AM |
| Davita (DVA) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - April 26 at 1:40 AM |
| How Highmark and a provider are working to lower the cost of dialysis care
finance.yahoo.com - April 24 at 5:38 PM |
| DaVita and Methodist Specialty and Transplant Hospital Collaborate to Launch Technology Designed to Help Improve ...
www.prnewswire.com - April 24 at 8:16 AM |
| DaVita and Methodist Specialty and Transplant Hospital Collaborate to Launch Technology Designed to Help Improve Transplant Readiness of Patients
finance.yahoo.com - April 24 at 8:16 AM |
| DaVita Recognized as a LearningElite Company by Chief Learning Officer Magazine
finance.yahoo.com - April 23 at 5:16 PM |
| DaVita Releases 10th Annual Community Care Report
finance.yahoo.com - April 19 at 8:12 AM |
DaVita (NYSE:DVA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
DaVita (NYSE:DVA) Income Statement, Balance Sheet and Cash Flow Statement
DaVita (NYSE DVA) Stock Chart for Sunday, May, 27, 2018
Loading chart…
